References
- Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell75(5), 843–854 (1993).
- Alberts B. Model organisms and human health. Science330(6012), 1724 (2010).
- Gerstein MB, Lu ZJ, Van Nostrand EL et al. Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science330(6012), 1775–1787 (2010).
- Roy S, Ernst J, Kharchenko PV et al.; modENCODE Consortium. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science330(6012), 1787–1797 (2010).
- Blaxter M. Genetics. Revealing the dark matter of the genome. Science330(6012), 1758–1759 (2010).
- Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug. Discov.9(10), 775–789 (2010).
- Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol.28(10), 1069–1078 (2010).
- Perry AS, Watson RW, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol.7(12), 668–680 (2010).
- Ambros V. The functions of animal microRNAs. Nature431, 350–355 (2004).
- Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell136, 215–233 (2009).
- Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res.19, 92–105 (2009).
- Volinia S, Calin GA, Liu CG et al. A microRNA expression signature in human solid tumors defines cancer targets. Proc. Natl Acad. Sci. USA103, 2257–2261 (2005).
- Yang N , Kaur S, Volinia S et al. MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res.68, 10307–10314 (2008).
- Bonci D , Coppola V, Musumeci M et al. The miR-15a–miR-16–11 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med.14, 1271–1277 (2008).
- Linsley PS , Schelter J, Burchard J et al. Transcripts targeted by the microRNA-16 family cooperatively regulates cell cycle progression. Mol. Cell Biol.27, 2240–2252 (2007).
- Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
- Lechner M, Boshoff C, Beck S. Cancer epigenome. Adv. Genet.70, 247–276 (2010).
- Heard E, Tishkoff S, Todd JA et al. Ten years of genetics and genomics: what have we achieved and where are we heading? Nat. Rev. Genet.11(10), 723–733 (2010).
- Werner T. Next generation sequencing in functional genomics. Brief. Bioinform.11(5), 499–511 (2010).
- Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature461(7261), 218–223 (2009).
- Hartwell LH, Hopfield JJ, Leibler S, Murray AW. From molecular to modular cell biology. Nature402, C47–C52 (1999).
- Tamsir A, Tabor JJ, Voigt CA. Robust multicellular computing using genetically encoded NOR gates and chemical ‘wires’. Nature469(7329), 212–215 (2010).
- Morris MK, Saez-Rodriguez J, Sorger PK, Lauffenburger DA. Logic-based models for the analysis of cell signaling networks. Biochemistry49, 3216–3224 (2010).
- Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer2(5), 331–341 (2002).
- Zhao X, Pan F, Holt CM, Lewis AL, Lu JR. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin. Drug Deliv.6(7), 673–686 (2009).